FOXP4

Across TCGA pan-cancer cohorts, FOXP4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FOXP4 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FOXP4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FOXP4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where FOXP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.781	0.996	.001	36	view →
LSCC	DFS	Median	All	0.992	0.881	.005	33	view →
PDAC	OS	Quartile	All	0.667	0.299	.012	9	view →
HNSC	DFS	Median	IV	0.545	0.764	.021	3	view →
GBM	OS	Median	All	0.851	0.601	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FOXP4–LUAD (DFS)

Open the LUAD breakdown →